Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145 - PubMed (original) (raw)

Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145

J C Bremner et al. Br J Cancer. 1992 Dec.

Free PMC article

Abstract

The effect of combining photodynamic therapy (PDT) and bioreductive drugs has been investigated using the RIF-1 experimental murine tumour. Light was delivered interstially to the tumour at 675 nm using a single optical fibre attached to an argon-ion dye laser. The photosensitizer was disulphonated aluminium phthalocyanine (AlS2Pc) and the bioreductive drugs were the dual function nitroimidazole RSU1069 and its pro-drug RB6145. Varying the time between administration of the photosensitizer and light delivery (TL) from 30 min to 24 h had little influence on the extent of the anti-tumour effect of PDT alone, as measured by the regrowth delay endpoint. When the bioreductive drug was included in the treatment, administered 20 min before light irradiation, regrowth delay was greatly increased. The effectiveness of the combined treatment was optimum for short values of TL (about 1 h). Fluorescence microscopy was used to investigate the distribution of the photosensitizer within the tumours. This showed that the compound was mainly confined to the tumour vasculature over the first few hours post-treatment. The high efficacy of the combined treatment of PDT and bioreductive drugs for short values of TL suggest that photodynamic action, during the period when the photosensitizer AlS2Pc is confined to the vasculature, enhances the severity of tumour hypoxia which is sufficient to induce activation of the bioreductive drugs.

PubMed Disclaimer

Similar articles

• Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
  Bremner JC, Bradley JK, Adams GE, Naylor MA, Sansom JM, Stratford IJ. Bremner JC, et al. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):329-32. doi: 10.1016/0360-3016(94)90284-4. Int J Radiat Oncol Biol Phys. 1994. PMID: 8195028
• Bioreductive drugs and the selective induction of tumour hypoxia.
  Bremner JC, Stratford IJ, Bowler J, Adams GE. Bremner JC, et al. Br J Cancer. 1990 May;61(5):717-21. doi: 10.1038/bjc.1990.161. Br J Cancer. 1990. PMID: 2110814 Free PMC article.
• A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
  Wood PJ, Horsman MR, Khalil AA, Steinberg F, Streffer C, Overgaard J, Stratford IJ, Adams GE. Wood PJ, et al. Acta Oncol. 1996;35(8):989-94. doi: 10.3109/02841869609100716. Acta Oncol. 1996. PMID: 9023383
• The experimental development of bioreductive drugs and their role in cancer therapy.
  Workman P, Stratford IJ. Workman P, et al. Cancer Metastasis Rev. 1993 Jun;12(2):73-82. doi: 10.1007/BF00689802. Cancer Metastasis Rev. 1993. PMID: 8375022 Review.

Cited by

• Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
  Curnow A, Perry A, Wood M. Curnow A, et al. Photodiagnosis Photodyn Ther. 2019 Mar;25:157-165. doi: 10.1016/j.pdpdt.2018.12.005. Epub 2018 Dec 13. Photodiagnosis Photodyn Ther. 2019. PMID: 30553949 Free PMC article.
• An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
  Anayo L, Magnussen A, Perry A, Wood M, Curnow A. Anayo L, et al. Lasers Surg Med. 2018 Jul;50(5):552-565. doi: 10.1002/lsm.22809. Epub 2018 Mar 31. Lasers Surg Med. 2018. PMID: 29603761 Free PMC article.
• Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy.
  Wang Y, Xie Y, Li J, Peng ZH, Sheinin Y, Zhou J, Oupický D. Wang Y, et al. ACS Nano. 2017 Feb 28;11(2):2227-2238. doi: 10.1021/acsnano.6b08731. Epub 2017 Feb 6. ACS Nano. 2017. PMID: 28165223 Free PMC article.
• Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
  Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Lash CJ, et al. Br J Cancer. 1998 Aug;78(4):439-45. doi: 10.1038/bjc.1998.512. Br J Cancer. 1998. PMID: 9716024 Free PMC article.

References

1. 1. Br J Cancer. 1991 Nov;64(5):875-9 - PubMed
2. 1. Br J Cancer. 1991 Dec;64(6):1108-15 - PubMed
3. 1. Cancer Res. 1989 Oct 15;49(20):5664-70 - PubMed
4. 1. Photochem Photobiol. 1986 Jun;43(6):691-9 - PubMed
5. 1. Cancer Res. 1988 Jun 1;48(11):3040-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal